Health X Platform Q1 FY27 Earnings Call — Analysis (NSE: HEALTHX)

Revenue surges 58% to ₹440 Cr with PAT turning positive, but CEO’s positive EBITDA claim conflicts with CFO’s reported loss

17 Aug 2026 · Analysis by Alpha Inflection

Result quality: watch — Margin pressure. Management sentiment: optimistic.

The take

Q1FY27 Revenue (YoY) ₹440 Cr ( +58% YoY ) . New guidance — Q3FY27 retailershakti segment ebitda positive EBITDA . New story: Capital-efficient platform model .

Results

Q1 FY27 revenue ₹440 Cr (+58% YoY, +16% QoQ); gross margin 7.8% (+50 bps QoQ); EBITDA loss ₹15 Cr narrowed from ₹20 Cr QoQ; PAT ₹2 Cr vs loss ₹13 Cr QoQ

Financial highlights

Guidance

RetailerShakti on track for positive EBITDA by Q3 FY27; FY27 consolidated gross margin to sustain 8%+ with longer-term target of ~12%

What management committed to

• RetailerShakti is expected to make positive EBITDA in Q3 this financial year (Q3 FY27) — positive EBITDA, Q3FY27
• Consolidated gross margin will be maintained at 8% plus for the entire year FY27 — 8% plus, FY27
• Consolidated gross margin will reach around 12% eventually, in line with industry — around 12%, down the line, as scale is achieved
• AI-monitored RetailAir product will be launched for [RetailerShakti] retailers in the current quarter (Q2 FY27) and success will be confirmed in the next quarter (Q3 FY27) — Q2FY27
• Existing plus side-extension fulfilment infrastructure is sufficient to support revenue up to ₹3,000 Cr — up to ₹3,000 Cr, by ~2028 as inferred
• New warehouse facilities will be set up in [Patna] and [Lucknow], with construction starting in the next 2-3 months — Q2FY27
• Approximately 50% of existing Healthbuddies will be converted into JITO pharmacies in the next 3 months — 50% of Healthbuddies, Q2FY27
• Wallet share per retailer will be doubled through the Retail Air SaaS tool — double
• [Health X] market share in West Bengal will double from the current 3-4% to around 7% in the next 2-3 years — around 7%, next 2-3 years

Key themes

Capital-efficient scale-up with private label margin lever

How the narrative shifted

• Capital-efficient platform model: Management positions the business as uniquely capital-efficient by avoiding depreciation-heavy retail/physical infrastructure, running 28-day working capital, and building revenue organically without acquiring it, aiming for direct cash-flow generation from revenue.
• JITO private label margin accelerator: JITO, with >50% gross margin and priced up to 60% below branded alternatives, is framed as a dual lever for affordability and margin expansion; still at infancy but growing rapidly (₹0.79 Cr in Q1), with path to becoming a meaningful mix shift.
• Geographic expansion into underpenetrated markets: The platform is replicating its model from West Bengal into Odisha, Bihar, Jharkhand, Chhattisgarh, and the North, with the Northeast being the fastest-growing region; management cites IPM data that new consumers are entering pharmacy for the first time, positioning Health X to capture this demand.
• AI and tech as competitive moat: Retail Air, an AI-enabled SaaS for retailers to automate inventory, is positioned as a tool to dramatically reduce retailer working capital while increasing Health X wallet share; launch imminent, framing helps defend ongoing tech burn.
• SastaSundar B2C investment phase: Management openly states it does not seek EBITDA positivity for SastaSundar in the next 2-3 years, framing investment in technology and brand acquisition as a strategic necessity that will yield high-return B2C revenue later, akin to the earlier Flipkart deal.
• Supportive macro tailwinds in healthcare access: Management notes rising first-time medicine buyers in India’s tier-2/3 cities as a secular demand driver that supports both generic demand and private-label substitution.

Operational commentary

• RetailerShakti grew 48% YoY, nears EBITDA breakeven; 69.4% of orders above ₹2,500, 40,000 pharmacies active in last 30 days
• SastaSundar grew 44% YoY with 69.2% of orders above ₹1,000, building B2C via Health Buddy franchisees; currently EBITDA-negative due to tech/brand investment
• JITO private label revenue tripled QoQ to ₹79 lakh at >50% gross margin; 19 Healthbuddies converted, 25 in pipeline, new standalone franchise channel being created
• Geographic expansion beyond West Bengal: entered Odisha, Bihar, Jharkhand, Chhattisgarh, UP, Haryana, Rajasthan; 30% revenue from outside West Bengal, Northeast fastest growing
• Own fulfilment centres: Noida operational, Guwahati expansion underway; existing warehousing capacity supports up to ₹3,000 Cr revenue; new warehouses planned in Ranchi, Patna, Lucknow
• AI-based SaaS 'Retail Air' for automated retailer inventory management planned for launch in Q2 FY27 to double wallet share
• Working capital cycle at ~28 days (~8% of revenue); all logistics riders on payroll to ensure quality
• Demerger/merger scheme progressing, responsive to stock exchange queries

Analyst Q&A

• Q. What were the RetailerShakti gross margin and EBITDA margin in Q1 FY27?

  Gross margin around 7.8%; closer to breakeven at EBITDA, expect positive EBITDA in Q3 this financial year.

• Q. What is the potential trajectory and revenue contribution of JITO private label, and how does it impact gross margin?

  Agreed with the analyst’s trajectory suggestion and said internal plans suggest surpassing that, but declined to give any specific guidance figures.

• Q. Can you provide the gross margin and EBITDA margin specifically for the SastaSundar (Health Buddy) platform, and split other expenses?

  Explained the philosophy of building B2C without shops, stated that they do not look at EBITDA for SastaSundar currently, and could not give segment margins; gave a rough burn split later (25% branding, 40-45% tech, 30% acquisition) but not exact numbers.

• Q. Why is the timeline for EBITDA breakeven being extended by 2-3 years?

  Clarified that RetailerShakti timeline is unchanged; the overall delay is because of B2C investment, which was never expected to break even soon; evaded giving exact SastaSundar standalone burn.

• Q. Will the company provide P&L split by business segments (RetailerShakti vs SastaSundar)?

  Acknowledged the request but stated that deep integration of procurement, fulfilment, and tech makes carving out difficult; promised to do it when systems are ready, without a timeline.

View source

Research and educational content only. Not investment advice.